A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of High Doses of Eteplirsen, Preceded by an Open-label Dose Escalation, in Patients With Duchenne Muscular Dystrophy With Deletion Mutations Amenable to Exon 51 Skipping

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 27 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eteplirsen (Primary)
Indications Duchenne muscular dystrophy
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms MIS51ON
Sponsors Sarepta Therapeutics

Most Recent Events

26 Dec 2024 Planned End Date changed from 30 Nov 2024 to 31 Oct 2026.
26 Dec 2024 Planned primary completion date changed from 30 Nov 2024 to 31 Oct 2026.
07 Jun 2024 This trial has been completed in Ireland.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight